Avanir Pharmaceuticals Inc  

(Public, NASDAQ:AVNR)   Watch this stock  
Find more results for AVNR
16.85
-0.14 (-0.82%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.85 - 16.98
52 week 2.65 - 17.05
Open 16.94
Vol / Avg. 13.89M/7.83M
Mkt cap 3.26B
P/E     -
Div/yield     -
EPS -0.31
Shares 193.76M
Beta 0.93
Inst. own 84%
Feb 9, 2015
Avanir Pharmaceuticals Annual Shareholder Meeting (Estimated) Add to calendar
Dec 10, 2014
Q4 2014 Avanir Pharmaceuticals Inc Earnings Release
Oct 15, 2014
Avanir Pharmaceuticals Investor Briefing - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -43.15% -43.85%
Operating margin -41.18% -40.97%
EBITD margin - -39.07%
Return on average assets -26.61% -26.33%
Return on average equity -33.29% -34.56%
Employees 484 -
CDP Score - -

Address

Suite 200, 20 Enterprise
ALISO VIEJO, CA 92656
United States - Map
+1-949-3896700 (Phone)
+1-949-3896701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Officers and directors

Craig A. Wheeler Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Keith A. Katkin President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Christine G. Ocampo CPA Principal Financial Officer, Vice President - Finance
Age: 41
Bio & Compensation  - Reuters
Joao Siffert M.D. Senior Vice President - Research and Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Gregory J. Flesher Senior Vice President - Corporate Development, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Rohan Palekar Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Hans Edgar Bishop Independent Director
Age: 49
Bio & Compensation  - Reuters
David J. Mazzo Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Corinne H. Nevinny Independent Director
Age: 54
Bio & Compensation  - Reuters